Clinical Trials Webinars

This webinar will explore the latest trends in the clinical trial industry, emphasizing direct-to-patient trial strategies and their impact on diversity, equity and inclusion (DEI). Reaching marginalized communities is a critical component for fulfilling study enrollment, yet these communities often face unique challenges.One significant hurdle is the financial burden placed on patients due to the leveraging of patient insurance, which can hinder study enrollment and impact efforts to improve clinical trial diversity in the United States. Current industry trends are centered on patient-centric approaches such as DEI, accelerated start-up timelines and decentralized clinical trials.Prioritizing patient-centricity can significantly enhance patient experience and enrollment, leading to more successful clinical trials. In addition, as clinical trial sites manage numerous studies simultaneously, it is essential to develop supply strategies that simplify the management of investigational medicinal products (IMPs) and non-IMPs (NIMPs).This webinar will dive into how patient-centric supply strategies can address these complexities, improve trial efficiency and support clinical trial diversity. Through case studies, the featured speakers will examine various sourcing options for sponsors, highlighting their benefits and drawbacks for sponsors, patients and sites. Additionally, the discussion will cover how comparator drug supply vendors handle complex trial designs and access to specialty drugs, ensuring that patient needs are met efficiently.Register for this webinar to learn about innovative, on-demand local sourcing solutions, methods to minimize cost and waste in clinical trials and how clinical trial diversity can benefit both sites and patients.Who Should Attend?This webinar will appeal to professionals in the following fields:Vendor Managers/Clinical Vendors ManagerClinical Trial Operations/Supplies Management/Supply ConsultantClinical Trial Comparator Managers/Clinical Trial Sourcing ManagersClinical Supply PlanningStrategy Lead Comparator ManagersClinical Trial ManagersClinical research organisationsWhat You Will LearnAttendees will gain insights into:How direct-to-patient strategies and patient-centric supply chain solutions can enhance clinical trial diversityHow patient centricity can significantly enhance patient experience and enrollmentThe challenges of leveraging patient insurance and how innovative approaches can alleviate financial burdensSpeakers: Samit Bhatt - Vice President, Clinical Trial Patient Solutions, Myonex; Todd Luckritz - Associate Director, Clinical Trial Patient Solutions, Myonex.

As more and more clinical trials are conducted internationally, with a higher level of protocol complexity, and with increased competition to get medical products to market faster globally, the need for efficient and streamlined clinical product development is greater than ever.Many clinical teams have experienced delays or bottlenecks in their programs as a result of not getting accurate local-language documentation to sites quickly enough. With companies working to bring innovative therapies to market faster, the effective localization of clinical documentation has never been more critical for success and staying competitive in a constantly evolving landscape.This webinar will bring together industry leaders to explore the critical role of centralized localization in accelerating clinical timelines for global studies. During this webinar, the expert speakers will discuss how centralizing localization of documentation for global studies with the aid of new technologies, including artificial intelligence (AI), can significantly accelerate clinical and product launch timelines.In this webinar, they will also discuss practical ways of leveraging technology automation and AI to streamline the localization process, and how these innovative tools have transformed the way clinical documentation is created and managed, offering unprecedented speed, accuracy and scalability. Through real-world application and case studies, the attendees will discover how leading companies have leveraged these approaches to overcome some of the greatest challenges in clinical product development across multiple languages and regions. One such case study will be a close examination of the clinical programs for vaccines and other treatments for COVID-19, and an analysis of the tactics used to meet unprecedented timelines in those studies that can bring similar time efficiencies to all programs.Register for this webinar today to gain insights into actionable strategies to reduce clinical timelines on a global scale, and to gain great clarity on how a centralized approach to localization can drive efficiency, enhance compliance and ultimately help in clinical product development.Who Should Attend?This webinar will appeal to professionals in the following fields:Clinical operationsRegulatory affairsMedical writingClinical researchPatient recruitmentMedical communicationsWhat You Will LearnAttendees will learn about: How centralizing localization of clinical documentation can drastically reduce timelines for global studiesPractical methods for leveraging technology automation and AI to streamline the localization processInsights from real-world case studies on overcoming challenges in clinical product developmentSpeakers: Kathleen Ruddy - Process & Standards Lead, Global Site & Study Operations, Pfizer; Kristofer Carilli - Senior Manager, Study Startup Management, AbbVie; Quantes Randle - Associate Director, Clinical Operations, Alexion.Moderator: Alexandra Farrell - Regional Director, TransPerfect Life Sciences

Join our upcoming webinar to learn about the FINE-ONE study, which is investigating an innovative treatment aimed at delaying CKD progression in individuals with type 1 diabetes. Shape the future of kidney patient care by learning how you can get involved!Speakers: Paul T. Conway - AAKP Chair of Policy and Global Affairs; Sylvia Rosas, MD, MSCE - Associate Profesor of Medicine, Joslin Diabetes Center, Harvard Medical School.

In this webinar, find out how to optimise oncology clinical trials using digital tools to accelerate decision-making.Oncology clinical trials present some of the most complex challenges across clinical research, impacting enrolment, efficiency, and access. Thankfully, our industry is afforded a unique opportunity to address these issues with the evolving regulatory landscape, the burgeoning field of digital health technologies (DHTs), and the increasing adoption of decentralised and digital trial methods.The US Food and Drug Administration (FDA)’s recent guidance on Direct-to-Patient (DTP) approaches, electronic Patient-Reported Outcomes (ePROs), and DHTs paves the way for incorporating patient-centric digital tools into trials.According to PwC, the use of DHTs in clinical trials has grown by 97 percent within the last five years, and Tufts recognises that the appetite for collecting digital endpoints has doubled every three years since 2015.As DHTs begin to help researchers define the new normal, it’s important to have the right strategy to define how you collect the right data to improve efficiency and experience. Learn how top 10 pharmaceutical companies are using a combination of DHTs, ePROs, clinical trial platforms and more, to ease oncology research and drastically reduce timelines. Key learning points- The right questions to ask your team to help define a digital strategy as part of your clinical development programme. - Why the expanded use of digital measures and biomarkers will continue to accelerate clinical development timelines.- How global pharmaceutical companies are benefiting from Medable’s novel approaches and technology to accelerate decision-making in oncology.Speaker: Musaddiq Khan – Vice President, Customer Value – Digital Outcomes & TA Strategy at Medable

Delve into the innovative journey of developing a new medicine using the Inhaled Oxytocin project as a case study. This technology was devised and initially developed at Monash University and is now entering clinical development in collaboration with GSK and philanthropic funding partners. Our guest speaker, Associate Professor Pete Lambert, from the Department of Pharmacy and Pharmaceutical Sciences at Monash University, brings over 20 years of expertise in pharmaceutical product development.KEY TOPICS:- Development pathway for new medicines- Proof of concept- Phase 2 clinical development- Running not-for-profit programs- Partnering with pharmaceuticalsSPEAKER:Pete Lambert, Pharmacy and Pharmaceutical Sciences, Monash UniversityABOUT PETE LAMBERT:Peter is a pharmaceutical scientist and programme director specialising in global health R&D. He currently leads the inhaled oxytocin project seeking to develop a novel oxytocin product to better manage postpartum haemorrhage in low resource settings.He is also a co-coordinator of the Global Health Therapeutic Program Area at Monash Institute of Pharmaceutical Sciences.Originally trained as a pharmacist, Pete has 20+ years experience in product development in the pharmaceutical industry.

Bringing together best practices in genomics, flow cytometry, biomarkers and clinical trial operations for successful CAR T-cell therapy clinical trials. This webinar emphasizes the challenges encountered and the importance of customized solutions in genomics, flow cytometry, biomarkers and clinical trial operations for successful CAR T-cell therapy clinical trials. The expert speakers will showcase the criticality of early engagement through two case studies, demonstrating how it allows for the design of tailored trials. They will then share best practices for overcoming challenges related to (1) monitoring CAR T-cells, (2) patient safety assurance and (3) assessment of therapy response. Join Cerba Research’s webinar to learn more about customized solutions for successful CAR T-cell therapy clinical trials and stay tuned for subsequent webinars and podcasts on their other CGT solutions.

This webinar aims to enhance understanding of Persistent Pulmonary Hypertension of the Newborn (PPHN), including its underlying physiology, diagnosis, and management, while emphasizing the collaborative efforts between neonatologists, paediatric intensivists and cardiologists to optimize patient care and outcomes. Our neonatologist speaker, Prof. Manuel Sánchez Luna, will discuss the importance of early recognition and therapeutic intervention in managing PPHN and key therapeutic strategies to improve outcomes and prevent mortality in the extremely severe cases. In addition, Prof. Sánchez Luna will address the utilization of non-invasive monitoring techniques, including pre- and post-ductal oxygen saturation, volumetric capnometry, and heart ultrasound, to identify PPHN and monitor response to specific therapies. By joining this session, you will also get insights from our cardiologist speaker, Prof. Maurice Beghetti, on the potential cardiac causes that may mimic PPHN in neonates and the importance of differentiating between cardiac and lung disease-induced pulmonary hypertension for appropriate treatment selection. Prof. Beghetti will also highlight different etiologies of PPHN and emphasize the importance of excluding cardiac lesions responsible for PPHN-like presentation. Target audience of this webinar: ICU Doctors in training – PICU, NICU and CICU; Cardiology doctors in training, ICU nurses, ECMO specialists, and other Allied Health Professionals. *This webinar is supported by an unrestricted educational grant from Masimo.

Join The Journal of Cardiovascular Aging for a webinar featuring Sanjiv Sam Gambhir, M.D., Ph.D. as he lectures on Stem Cell & Genomics: From Precision Medicine to Clinical Trial in Dish Time. The webinar will take place on April 8, 2024, at 9:00 AM (New York time, UTC-4).

The tumor microenvironment is a complex mix of cancer cells, immune cells, and other components that all play a part in tumor progression, metastasis, and therapy responses. Understanding the highly dynamic nature of the tumor microenvironment and the factors that influence those changes is essential for developing effective precision oncology therapies. Innovations in computational pathology and artificial intelligence, coupled with novel multiplex biomarker assays, are critical to fostering that understanding. Together, they are paving the way for scientists to better characterize the unique cancer cell populations, spatial relationships, and differences in immune responses in the tumor microenvironment.In this GEN webinar, Michael Downing, Senior Image Analysis Scientist at Ultivue, will review the state of the field and introduce Ultivue’s two core platform technologies: InSituPlex® assays, and its proprietary Spatial Image Analysis pipeline featuring UltiStacker.AI™ and UltiAnalyzer.AI™. He will also explain how these technologies work together to provide high confidence insights from tumor data for scientists developing precision cancer therapies.Topics covered in the webinar will include:How AI-supported spatial image analysis together with Ultivue’s InSituPlex assays deliver accurate and scalable insights into the biology of the tumor microenvironment.How Ultivue’s 12-plex assay verification demonstrates its readiness to provide a comprehensive view of the tumor microenvironment.A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

In the United States, public health and health care delivery have largely taken different and siloed approaches, with health care focused on the treatment of individuals and public health centered on the total population within a geographic region. Collaboration between the sectors is essential to advancing both health outcomes and equity—a lesson driven home during the COVID-19 pandemic. In a new webinar, Manatt Health will provide an in-depth look at the innovative ways California health agencies are working together to bridge the gap between public health and managed care health care delivery—and what other states can learn from the California model.